Abstract:In clinical studies, the toxicity of platinum-based antitumor drugs limits their use. DNA is the most widely studied target of metal-based complexes. Thus, nuclear targeting and selective killing have become the purpose of ruthenium complex design. We synthesized a carboline derivative and its ruthenium complex, NBD and NBD-Ru, and characterized their properties. UV spectra were used to monitor their stability. Transmission electron microscopy and dynamic light scattering were used to identify the self-assembly properties. Inductively coupled plasma mass spectrometry was used to assay the distribution of the Ru complexes in cells with or without transferrin. Besides, the tumor cell killing activities with or without transferrin were detected by MTT assay. An imaging flow cytometer was applied to observe the fluorescence further to identify the cellular distribution. The effects of NBD and NBD-Ru on DNA and the cell cycle were also measured. In vivo, the antitumor and antimetastatic activities of NBD and NBD-Ru were assessed in S180 and LLC tumor-bearing mice. We found that introducing Ru improved the solubility and stability, enabling NBD-Ru to self-assemble into nanoparticles with the EPR effect. At the same time, binding affinity with transferrin increased significantly after complexation, allowing NBD-Ru could target and selectively kill tumors via Tf/TfR pathway. More interestingly, ruthenium assisted the complex in achieving nuclear penetration, which can kill tumor cells by interacting with DNA. In vivo experiments further verified our conclusion in vitro. NBD-Ru could inhibit not only the growth of a primary tumor but also lung metastasis, which was related to the killing effect of the complex on tumor cells (ki67) and inhibition of neovascularization (CD31). At the same time, the systemic toxicity of the ruthenium complex in vivo was reduced because of the targeting effect, and the biosafety was improved. In conclusion, we found that ruthenium assisted in nuclear targeting and selective killing in vitro and in vivo.

Biocompatible Ruthenium Polypyridyl Complexes As Efficient Radiosensitizers.

Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells

Sonoinduced Tumor Therapy and Metastasis Inhibition by a Ruthenium Complex with Dual Action: Superoxide Anion Sensitization and Ligand Fracture

Biodegradable Ruthenium‐Rhenium Complexes Containing Nanoamplifiers: Triggering ROS‐Induced CO Release for Synergistic Cancer Treatment

The ruthenium complex assists in nuclear targeting and selective killing of tumor cells

Mixed-valence Pt(0)/Pt 2+ nanoassemblies as high-Z radiosensitizers and metallo-immune regulators for potent radiotherapy of breast cancer

X-ray sensitive selenium-containing Ru complexes sensitize nasopharyngeal carcinoma cells for radio/chemotherapy

Multifunctional nanocomposites utilizing ruthenium (II) complex/manganese (IV) dioxide nanoparticle for synergistic reinforcing radioimmunotherapy

A lysosome-targeted ruthenium(II) polypyridyl complex as photodynamic anticancer agent

Trinuclear ruthenium(II) polypyridyl complexes: Evaluation as photosensitizers for enhanced cervical cancer treatment

Selenium-containing metallodrug overcomes cervical cancer radioresistance by physical-chemical dual sensitization

Homo and heterometallic ruthenium and platinum complexes with multiple targets for therapeutic applications: a review

Synthesis and biological evaluation of zwitterionic half-sandwich Rhodium(III) and Ruthenium(II) organometallic complexes

Substituent‐Modulated Excited Triplet States and Activities of Ruthenium Complexes for Dual Photodynamic/Sonodynamic Therapy to Cisplatin‐Resistant Non‐Small Cell Lung Cancer

Increasing the cytotoxicity of Ru(II) polypyridyl complexes by tuning the electron donating ability of 1,10-phenanthroline ligands

Fortuitous synthesis of unsaturated half-sandwich Ruthenium(II) complexes via solvent-involved rearrangement and their biological evaluation

Ruthenium Complexes as Promising Candidates against Lung Cancer

Supramolecular Radiosensitizer Based on Hypoxia‐Responsive Macrocycle

Recent Advances in Ruthenium and Platinum Based Supramolecular Coordination Complexes for Antitumor Therapy

Designing Bimetallic Metal‐Organic Framework‐Based Heterojunction Radiosensitizer for Enhanced Radiodynamic Therapy and Immunotherapy

Multi-targeted organometallic ruthenium(II)-arene anticancer complexes bearing inhibitors of poly(ADP-ribose) polymerase-1: A strategy to improve cytotoxicity.